Loading clinical trials...

Neurofeedback in Individuals With Substance Use Disorders | Clinical Trials | Clareo Health

TERMINATEDNA

Neurofeedback in Individuals With Substance Use Disorders

NCT04188288•Yale University

Summary

The aim of this study is to train individuals with opioid use disorder to control their brain activity in a way that has been associated with their symptoms. Participants in the experimental group will be given direct feedback regarding their brain activity while they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to learn to control their brain activity during these feedback sessions. A separate group of participants will be given a control form of feedback that we do not believe can have clinical benefits. Our primary hypothesis is that the neurofeedback training will reduce opioid use and clinical features of opioid use disorder more than the control feedback.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. non-methadone opioid positive urine screen (as assessed during standard treatment) or indicated via Utox or self-reported past-month opioid use at screening
•2. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for opioid use disorder, as assessed via structured clinical interview (SCID)
•3. ≥3 months of methadone treatment

Exclusion Criteria

•1. Having any current neurologic or psychiatric disorders including current moderate to severe other DSM-5 substance use disorders with the exceptions of opioids, cocaine, tobacco and cannabis, as assessed using the SCID.
•2. Failure to pass a magnetic resonance imaging (MRI) screening
•3. Having significant underlying medical conditions requiring medications.
•4. Women who are pregnant or nursing
•5. Baseline scanning with excessive motion based on frame to frame displacement

Locations (1)

Yale New Haven Hospital

New Haven, Connecticut, United States

Key Dates

Start Date

July 1, 2021

Primary Completion Date

March 15, 2023

Completion Date

March 15, 2023

Last Updated

September 25, 2024

Enrollment

ACTUAL participants

Conditions

Opioid-Related Disorders

Interventions

Experimental feedback

DEVICE

Control feedback

DEVICE

fMRI

DEVICE

Tau PET Imaging in Opioid Use Disorder

NCT05651516

Opioid-Related Disorders

View study

ACTIVE_NOT_RECRUITINGNA

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

NCT05505227

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Neurofeedback in Individuals With Substance Use Disorders

Inclusion Criteria

Exclusion Criteria

Tau PET Imaging in Opioid Use Disorder

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Erector Spinae Plane Block Versus Serratus Anterior Plane Block

Social Work Assistance and Stipends for Housing (SASH)